Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Complete Title: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with
Relapse/Refractory AML
Trial Phase: I/II
Investigator: Mary-Elizabeth Percival
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.
Keywords:
- Leukemia, Acute Myeloid (AML)
- Myelodysplastic Syndromes (MDS)
- Leukemia, Chronic Myelomonocytic (CMML)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Mary-Elizabeth Percival
RG1121430
NCT04358393
A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with
Relapse/Refractory AML
Leukemia, Acute Myeloid (AML)
Myelodysplastic Syndromes (MDS)
Leukemia, Chronic Myelomonocytic (CMML)